Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$0.83
-$0.03-3.49%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 940.81M | 929.36M | 913.60M | 926.53M | 957.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 940.81M | 929.36M | 913.60M | 926.53M | 957.40M |
| Cost of Revenue | 345.63M | 344.11M | 339.67M | 339.89M | 349.98M |
| Gross Profit | 595.18M | 585.25M | 573.93M | 586.64M | 607.42M |
| SG&A Expenses | 401.36M | 389.85M | 379.77M | 393.14M | 403.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -607.30K | -1.75M | -1.73M | -5.39M | -2.95M |
| Total Operating Expenses | 746.38M | 732.21M | 717.71M | 727.63M | 750.76M |
| Operating Income | 194.43M | 197.16M | 195.88M | 198.90M | 206.64M |
| Income Before Tax | 129.82M | 127.82M | 126.57M | 122.38M | 139.07M |
| Income Tax Expenses | 39.95M | 41.15M | 42.80M | 38.14M | 43.23M |
| Earnings from Continuing Operations | 89.87 | 86.67 | 83.76 | 84.23 | 95.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -26.80M | -26.80M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.87M | 86.67M | 83.76M | 57.43M | 69.04M |
| EBIT | 194.43M | 197.16M | 195.88M | 198.90M | 206.64M |
| EBITDA | 214.90M | 217.19M | 215.65M | 219.52M | 226.83M |
| EPS Basic | 0.09 | 0.09 | 0.09 | 0.06 | 0.07 |
| Normalized Basic EPS | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| EPS Diluted | 0.09 | 0.09 | 0.09 | 0.06 | 0.07 |
| Normalized Diluted EPS | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| Average Basic Shares Outstanding | 3.92B | 3.90B | 3.91B | 3.92B | 3.88B |
| Average Diluted Shares Outstanding | 3.92B | 3.90B | 3.91B | 3.92B | 3.88B |
| Dividend Per Share | 0.03 | 0.04 | 0.04 | 0.07 | 0.06 |
| Payout Ratio | 59.66% | 49.00% | 49.24% | 69.11% | 42.07% |